Birsen Tozkoparan

Birsen Tozkoparan

Auto-generated profile, based on publicly available information

Birsen Tozkoparan

Hacettepe University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
GAGoknur Aktay
Goknur Aktay
BTBirsen Tozkoparan
Birsen Tozkoparan
MEMevlut Ertan
Mevlut Ertan
Promising antiinflammatory activity together with low ulcerogenic properties of some Michael addition products of thiazolo[3,2-b]-1,2,4-triazole-5(6H)-ones which have been synthesized in our previous study, prompted us to investigate their antioxidant properties. Since compound Ib has both antioxidant and antiinflammatory activities beside the lowest ulcerogenic incidence, it was selected for investigation of its inhibitory effect on various cyclooxygenase ezymes. It was found that while it did not inhibit cyclooxygenase-1 (COX-1) enzyme, there was a small inhibitory effect (17%) on COX-2 enzyme. We concluded that the diminished harmful effects on the stomach of this novel antiinflammatory compound were related to its antioxidant properties since it is ineffective on COX-1 enzyme. In conclusion, the compounds having both antioxidant and antiinflammatory activities with a lack of COX-1 enzyme inhibitory effect may improve the gastrointestinal safety profile of such compounds.

16 June 2022 in Acta Medica
Verified
Journal Article
Open access
PDF file
CSCeren Sucularlı
Ceren Sucularlı
BTBirsen Tozkoparan
Birsen Tozkoparan
SAS. Peri Aytac
S. Peri Aytac
Objective: Polypharmacology, interaction of one drug with multiple targets, emerged as an effective approach in drug discovery and development. Bioinformatics and cheminformatics methods are essential tools for determination of polypharmacological profiles of newly synthesized or known compounds and drugs. Previously, three novel triazolothiadiazine derivatives; 1h, 3c and 3h, have been shown to induce apoptosis and cause cell cycle arrest on liver cancer cells. The aim of this study is to find possible action mechanisms and potential targets for these three triazolothiadiazine derivatives, and to investigate their potential as new therapeutic agents by using computational methods. Materials and Methods: PASS software was used to identify biological activities and Swiss Target Prediction and BindingDB databases to predict potential targets for 1h, 3c and 3h. PDE4A, ALR and DUSP1 proteins were selected for molecular docking analysis following the protein modeling of the three proteins. Results: Activity prediction results show that 1h, 3c and 3h might have phosphatase and signal transduction pathway inhibitor, hepatocyte growth factor antagonist, anti-inflammatory and antifungal activities. These derivatives are predicted as inhibitors of several phosphodiesterases by activity and target prediction tools. Conclusion: Based on prediction and molecular docking results, it is proposed that these compounds may have therapeutic properties through new predicted targets.

13 July 2026 in ACS Omega
Verified
Journal Article
Open access
HTHayrünNisa TaşcI
HayrünNisa TaşcI
AAAhmet Avcı
Ahmet Avcı
NONadire ÖzEnver
Nadire ÖzEnver
Begüm Nurpelin Sağlık ÖzkanBegüm Nurpelin Sağlık Özkan
Begüm Nurpelin Sağlık Özkan
BTBirsen Tozkoparan
Birsen Tozkoparan
NKNesrin GökHan Kelekçi
Nesrin GökHan Kelekçi
Alzheimer’s disease (AD) benefits from multitarget-directed ligands (MTDLs) that can enhance cholinergic transmission while attenuating monoamine-oxidase-linked oxidative stress. Here, we report a benzoxazolinone-based propionyl thiosemicarbazide series, synthesized and fully characterized by infrared (IR) spectroscopy, 1H nuclear magnetic resonance (NMR), and high-resolution mass spectra (HRMS). The compounds showed consistent submicromolar inhibitory activity across AChE, BChE, MAO-A, and MAO-B in vitro. Several AChE potencies approached the reference donepezil, and selected BChE activities were within an order of magnitude of tacrine. Notably, 4bk′ (5-Me/benzyl) inhibited three targets (IC50: 0.029 ± 0.001 μM for AChE, IC50: 0.071 ± 0.003 μM for BChE, IC50: 0.048 ± 0.002 μM for MAO-B), and 4af′ (5-Cl/phenyl) showed a balanced profile (IC50: 0.025 ± 0.001 μM for AChE, IC50: 0.056 ± 0.002 μM for BChE, IC50: 0.095 ± 0.003 μM for MAO-A), 4ac′ (5-Cl/propyl) combined potent AChE and MAO-B inhibition (IC50: 0.035 ± 0.001 μM for AChE, IC50: 0.045 ± 0.002 μM for MAO-B), whereas 4ag′ (5-Cl/4′-Cl-phenyl) was strongly MAO-B-selective (IC50: 0.041 ± 0.001 μM for MAO-B). Antioxidant capacity was pronounced for para-substituted analogues. The efficient compounds 4bk′, 4af′, 4ac′, and 4ag′ presented quite low toxicity on healthy cells (cell survival % was above %70 for 4bk′, 4af′, and 4ac′, while it was around 64% for 4ag′) even when they were applied at 100 times higher concentrations than their IC50 values, which indicates that they are safe at effective doses. Moreover, assessment of the compounds at a concentration of 10 μM demonstrated no cytotoxic effects on either healthy BV-2 microglial cells or H9c2 rat myoblastoma cells. Docking and 100 ns molecular dynamics (MD) simulations (AChE: 4EY7; MAO-B: 2V5Z) supported stable binding for dual-active representatives (RMSD ∼1.5–2.8 Å). In silico ADME (QikProp) indicated compliance with Lipinski’s Rule of Five and Jorgensen’s Rule of Three. Collectively, this scaffold is tunable from MAO-B-selective to balanced MTDL profiles suitable for further AD-relevant optimization.

25 July 2026 in ACS Omega
Verified
Journal Article
Open access
AAAhmet Avci
Ahmet Avci
HTHayrünNisa TaşcI
HayrünNisa TaşcI
Begüm Nurpelin Sağlık ÖzkanBegüm Nurpelin Sağlık Özkan
Begüm Nurpelin Sağlık Özkan
BTBirsen Tozkoparan
Birsen Tozkoparan
NKNesrin GökHan Kelekçi
Nesrin GökHan Kelekçi
Janus kinases (JAKs) are central mediators of cytokine-driven signal transducer and activator of transcription (STAT) signaling, and dysregulation of the JAK–STAT axis is implicated in inflammatory, autoimmune, and neoplastic diseases. To identify new small-molecule inhibitors of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), we implemented an integrated virtual screening workflow combining structure-based docking and ligand-based prioritization using the InterBioScreen (IBS) compound library. A drug-likeness filter reduced 521,627 IBS molecules to 116,064 candidates, which were then docked into the ATP-binding sites of JAK1 (PDB ID: 4EI4) and JAK2 (PDB ID: 6VGL) using Glide SP; compounds were prioritized using docking score thresholds of <− 8.5 kcal/mol (JAK1) and <− 9.0 kcal/mol (JAK2), yielding 407 JAK1- and 298 JAK2-focused hits. Subsequent analysis shortlisted 42 candidates for enzymatic evaluation. In vitro kinase assays identified multiple nanomolar inhibitors, including compound 1–3 (IC50 = 0.032 μM) among the most potent for JAK1 and compound 2–8 (IC50 = 0.026 μM) for JAK2. Finally, 100 ns molecular dynamics (MD) simulations supported stable binding for representative complexes, with persistent hinge-region interactions for compound 1–3 in JAK1 (e.g., Glu957/Leu959) and compound 2–8 in JAK2 (e.g., Glu930/Leu932), consistent with a stable interaction network in the active site. Collectively, these results define validated IBS-derived hit scaffolds for further optimization and selectivity profiling toward JAK-targeted therapeutics.

19 May 2026 in Ankara Universitesi Eczacilik Fakultesi Dergisi
Verified
Journal Article
Closed access
ABAzime Boz
Azime Boz
BTBirsen Tozkoparan
Birsen Tozkoparan
Amaç: Gıdalara şeker tadı veren, ancak şeker içermeyen ve onun gibi kalori sağlamayan, şeker ikamesi olarak da bilinen tatlandırıcılar gıda endüstrisine 1800'lü yıllarda girmişler ve şu anda gıda maddelerinin temel bileşeni haline gelmişlerdir. "Şekersiz", "keto", "düşük karbonhidrat" veya "diyet" olarak etiketlenen gıdalar genellikle şeker yerine tatlandırıcı içermektedirler. Bunlar tatlıdan vazgeçemeyip ama kalori almak istemeyen kişiler ve özellikle diyabet hastaları tarafından yaygın olarak tercih edilen bileşenlerdir. Bu derleme, tatlandırıcılar hakkındaki bilgi düzeyini artırarak, doğal ve sentetik tatlandırıcıların sağlık üzerindeki etkilerini daha iyi anlamayı amaçlamaktadır.Sonuç ve Tartışma: Tatlandırıcılar, gıda endüstrisinde önemli bir yere sahip olmakla birlikte, kısa ve uzun vadeli etkileri üzerine yapılan araştırmalar halen tartışmalıdır. Mevcut olan klinik ve epidemiyolojik veriler, yapay tatlandırıcıların enerji dengesi, vücut ağırlığının korunması veya azaltılması ve diğer kardiyometabolik risk faktörleri ile ilgili olarak kalorili tatlandırıcıların yerini almasındaki faydaları hakkında kesin sonuçlara varmak için yetersizdir. Günümüzde optimum sağlık için hem şekerin hem de yapay tatlandırıcıların yalnızca asgari miktarda tüketilmesi önerilmektedir.